Patents by Inventor Thomas Gadek

Thomas Gadek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent number: 8871935
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: October 28, 2014
    Assignee: SARcode Bioscience Inc.
    Inventors: John Burnier, Thomas Gadek, Frederic Naud
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20140161872
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: October 3, 2013
    Publication date: June 12, 2014
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier, Min Zhong, Wang Shen, Johan D. Oslob, Kenneth Barr
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20140141062
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 22, 2014
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier, Min Zhong, Wang Shen, Johan D. Oslob, Kenneth Barr
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20140099387
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: August 8, 2013
    Publication date: April 10, 2014
    Applicant: Sarcode Bioscience Inc.
    Inventors: Thomas Gadek, John Burnier, Min Zhong, Wang Shen, Johan D. Oslob, Kenneth Barr
  • AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS
    Publication number: 20140079784
    Abstract: This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 aerosolized formulations of the present invention.
    Type: Application
    Filed: August 7, 2013
    Publication date: March 20, 2014
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: John Burnier, Thomas Gadek
  • COMPOSITIONS AND METHODS FOR TREATMENT
    Publication number: 20140073666
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: August 8, 2013
    Publication date: March 13, 2014
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier, Min Zhong, Wang Shen, Johan D. Oslob, Kenneth Barr
  • TOPICAL LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS
    Publication number: 20140051722
    Abstract: This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 topical formulations of the present invention.
    Type: Application
    Filed: August 7, 2013
    Publication date: February 20, 2014
    Applicant: SARCODE BIOSCIENCE INC.
    Inventors: John Burnier, Thomas Gadek
  • Compositions and methods for treatment of eye disorders
    Patent number: 8592450
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: November 26, 2013
    Assignee: SARcode Bioscience Inc.
    Inventors: Thomas Gadek, John Burnier
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent number: 8367701
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: February 5, 2013
    Assignee: SARcode Bioscience Inc.
    Inventors: John Burnier, Thomas Gadek, Frederic Naud
  • Compositions and Methods for Treatment of Eye Disorders
    Publication number: 20120232019
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: February 16, 2012
    Publication date: September 13, 2012
    Applicant: SARcode Bioscience Inc.
    Inventors: Thomas Gadek, John Burnier, Johan Oslob, Wang Shen, Kenneth Barr, Min Zhong
  • Crystalline Pharmaceutical and Methods of Preparation and Use Thereof
    Publication number: 20120107404
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Application
    Filed: November 4, 2011
    Publication date: May 3, 2012
    Applicant: SARcode Bioscience Inc.
    Inventors: John Burnier, Thomas Gadek, Frederic Naud
  • Compositions and methods for treatment of eye disorders
    Patent number: 8168655
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: May 1, 2012
    Assignee: SARcode Bioscience Inc.
    Inventors: Thomas Gadek, John Burnier
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Patent number: 8080562
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: December 20, 2011
    Assignee: Sarcode Bioscience Inc.
    Inventors: John Burnier, Thomas Gadek, Frederic Naud
  • Compositions and Methods for Treatment
    Publication number: 20110165228
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 21, 2011
    Publication date: July 7, 2011
    Applicant: SARcode Corporation
    Inventors: John BURNIER, Thomas GADEK, Min ZHONG, Wang SHEN, Johan D. OSLOB, Kenneth BARR
  • Compositions and Methods for Treatment
    Publication number: 20110165229
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: January 21, 2011
    Publication date: July 7, 2011
    Applicant: SARcode Corporation
    Inventors: John BURNIER, Thomas GADEK, Min ZHONG, Wang SHEN, Johan D. OSLOB, Kenneth BARR
  • COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS
    Publication number: 20100092542
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: July 23, 2009
    Publication date: April 15, 2010
    Inventors: John Burnier, Thomas Gadek, Wang Shen, Johan D. Oslob, Kenneth Barr
  • COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS
    Publication number: 20100092541
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Application
    Filed: July 23, 2009
    Publication date: April 15, 2010
    Inventors: John Burnier, Thomas Gadek, Min Zhong
  • Crystalline pharmaceutical and methods of preparation and use thereof
    Publication number: 20090298869
    Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
    Type: Application
    Filed: April 15, 2009
    Publication date: December 3, 2009
    Inventors: John Burnier, Thomas Gadek, Frederic Naud
  • Delivery of LFA-1 antagonists to the gastrointestinal system
    Publication number: 20090258069
    Abstract: The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1 antagonists to effect localized treatment.
    Type: Application
    Filed: April 15, 2009
    Publication date: October 15, 2009
    Inventors: John Burnier, Thomas Gadek
  • Aerosolized LFA-1 antagonists for use in localized treatment of immune related disorders
    Publication number: 20090257957
    Abstract: This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 aerosolized formulations of the present invention.
    Type: Application
    Filed: April 15, 2009
    Publication date: October 15, 2009
    Inventors: John Burnier, Thomas Gadek